Canadian Senate approves industry fees hike
This article was originally published in RAJ Devices
The Canadian Senate adopted on 26 May proposals by Health Canada to allow it to increase user fees to medical device (and pharmaceutical) companies to cover its growing costs and workload delivering regulatory services1. The proposals are expected to come into force in April 2011, officials have indicated.
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.